PHS
MYGN icon

PFM Health Sciences’s Myriad Genetics MYGN Stock Holding History

PFM Health Sciences’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-194,000
Closed -$87K – 71
2013
Q3 		$87K Buy
+194,000
New +$5.51M ﹤0.01% 72

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PFM Health Sciences's MYGN Position: Q4 2022 in Review

PFM Health Sciences sold out of Myriad Genetics (MYGN) in Q4 2022, closing a stake of 742,138 shares — an estimated $14.2M sold.

PFM Health Sciences first reported a position in MYGN in Q3 2013 and held it in 10 quarters. The position peaked at $94.5M in Q2 2021. 197 funds tracked by Wall St. Rank hold MYGN as of Q4 2022.

  • PFM Health Sciences reported no remaining Myriad Genetics position as of Q4 2022 after selling out during the quarter.
  • PFM Health Sciences sold 742,138 Myriad Genetics shares in Q4 2022, an estimated $14.2M.
  • PFM Health Sciences first reported a position in Myriad Genetics in Q3 2013 and held it in 10 quarters.
  • PFM Health Sciences's Myriad Genetics position peaked at $94.5M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2022.

Based on PFM Health Sciences's 13F filing for Q4 2022, filed 14 Feb 2023.